Pivotal Phase 3 trial (IOB-013/KN-D18) evaluating off-the-shelf therapeutic cancer vaccine IO102-IO103 in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with advanced ...

"In the third quarter, we delivered strong commercial results, maintained financial discipline, and... Trinity Capital Inc. ("Trinity"), a leading provider of diversified financial solutions to growth ...

Schrödinger, Inc. today announced a research collaboration and license agreement with Novartis to advance multiple development candidates into Novartis's portfolio for further development. The ...

Avid exemplifies this perfectly — the company operates in high-growth markets, producing complex biologics for leading ...

Italvacuum will attend the first edition of Process Innovation Asia Pacific Powered by ACHEMA from 19 to 21 November at the ...